Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Fixed‐dose combination aclidinium/formoterol vs formoterol · Non‐fatal serious adverse events
  Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 1.15 [0.82, 1.61]
  5 studies · 3140 participants
  Moderate
Direct match · question page
- Fixed‐dose combination aclidinium/formoterol vs placebo · Non‐fatal serious adverse events
  Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 1.12 [0.72, 1.74]
  4 studies · 2527 participants
  Moderate
Direct match · question page
- Tiotropium + LABA/ICS combination vs tiotropium · Serious adverse events (non‐fatal)
  Combination inhaled steroid and long‐acting beta₂‐agonist in addition to tiotropium versus tiotropium or combination… 2016 · Cochrane Headline outcomes only
  OR 0.86 [0.57, 1.3]
  4 studies · 1758 participants
  Low
Direct match · question page
- Fixed‐dose combination aclidinium/formoterol vs aclidinium alone · Non‐fatal serious adverse events
  Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 1.19 [0.79, 1.8]
  3 studies · 2473 participants
  Moderate

Fixed‐dose combination aclidinium/formoterol vs formoterol

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with formoterol (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 1.15 [0.82, 1.61]
5 studies · 3140 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs placebo

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 1.12 [0.72, 1.74]
4 studies · 2527 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs aclidinium alone

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with aclidinium alone (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 1.19 [0.79, 1.8]
3 studies · 2473 participants
Moderate

Tiotropium + LABA/ICS combination vs tiotropium

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).

1 finding from 1 review

Combination inhaled steroid and long‐acting beta₂‐agonist in addition to tiotropium versus tiotropium or combination… 2016 · Cochrane Headline outcomes only
OR 0.86 [0.57, 1.3]
4 studies · 1758 participants
Low